Bayer (Switzerland)

Recent publications and citations

Top Concepts

Top subject area publications in last 5 years

Collaboration Analysis

Publications from 2021 to 2026

Latest Publications

Filter IconFilter

Showing 10 of 96 papers

  • Open Access
  • Research Article

Use of Aflibercept 8mg for the Treatment of Diabetic Macular Edema in Italy: A Cost-Minimisation Analysis Based on an Indirect Treatment Comparison.

  • Mar 28, 2026
  • Advances in therapy
  • Paolo A Cortesi +6
  • Research Article

Hyperreflective Foci Contiguous With the Retinal Pigment Epithelium Associated With Visual Function in Aging, Early, and Intermediate Age-Related Macular Degeneration: MACUSTAR Study Report.

  • Mar 23, 2026
  • American journal of ophthalmology
  • Lukas Goerdt +15
  • Open Access
  • Research Article

Intravitreal aflibercept 8 mg versus 2 mg in Asian patients with neovascular age-related macular degeneration: 48-week analysis of the Phase 3 PULSAR trial.

  • Jan 01, 2026
  • Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
  • Andrew Chang +14
  • Research Article
  • Citations7

Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial.

  • Jan 01, 2026
  • Ophthalmology
  • Jean-François Korobelnik +25
  • Research Article

EE120 Can Intravitreal Aflibercept 8 mg Result in Decreased Treatment Burden and Treatment Costs in European Patients With Age-Related Macular Degeneration? Early Evidence From Clinical Practice

  • Dec 01, 2025
  • Value in Health
  • Megan Druce +2
  • Open Access
  • Research Article

Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP)

  • Nov 11, 2025
  • Future Oncology
  • Alicia K Morgans +20
  • Open Access
  • Conference Article

614 Treatment with diacylglycerol kinase (DGK) alpha specific inhibitor BAY2862789 exhibits combination potential with DGK zeta inhibition in biomarker assays during FIH monotherapy trial

  • Nov 01, 2025
  • Regular and Young Investigator Award Abstracts
  • Helge G Roider +27
  • Research Article

Résultats de qualité de vie liée à la santé (QVLS) avec le darolutamide dans l’essai de phase 3 ARANOTE

  • Oct 31, 2025
  • Progrès en Urologie - FMC
  • M Roupret +12
  • Research Article

2001P Molecular factors and ctDNA dynamics associated with clinical outcomes in patients with HER2-mutant NSCLC treated with sevabertinib (BAY 2927088): Exploratory analysis of the SOHO-01 study

  • Sep 01, 2025
  • Annals of Oncology
  • N Girard +19
  • Research Article

969P Real-world study of larotrectinib in patients with TRK fusion solid tumours: Interim analysis of ON-TRK

  • Sep 01, 2025
  • Annals of Oncology
  • J.c Trent +12
Cactus Communications logo

Copyright 2026 Cactus Communications. All rights reserved.